• OPEN AN ACCOUNT
Indian Indices
Sensex
78,624.92 530.28
( 0.68%)
Global Indices
Nasdaq
52,497.89 268.83
(0.51%)
Dow Jones
7,510.69 52.06
(0.70%)
Hang Seng
64,316.33 2,448.90
(3.96%)
Nikkei 225
10,879.26 -18.01
(-0.17%)
Forex
USD-INR
95.59 -0.10
(-0.11%)
EUR-INR
109.79 0.65
(0.59%)
GBP-INR
128.11 0.75
(0.59%)
JPY-INR
0.59 0.01
(1.09%)

EQUITY - MARKET SCREENER

National Standard (India) Ltd
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
504882
INE166R01015
141
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
NATIONSTD
44.53
499.6
EPS(TTM)
Face Value()
Div & Yield %
5.61
10
0
 

skipper ltd
USFDA inspects Cipla subsidiary's manufacturing unit in New York
Jul 18,2026

Cipla announced that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the company) located in Central Islip, Long Island, New York, USA, from 13 July 2026 to 17 July 2026 (EDT).

The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the company has received 1 (one) inspectional observation in Form 483.